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ThemostcommonmonogeniccauseofneonataldiabetesismutationinKCNJ11,whichencodesapotassiumchannelinpancreatic
beta cells. Some mutations in this gene, including Q52R, have been described in association with neurological deﬁcits, but
never with hepatic involvement. We report the second case of neonatal diabetes in a patient with a KCNJ11/Q52R mutation.
This patient’s clinical course did not include obvious neurological deﬁcits despite the presence of prematurity, but did include
transient hyperbilirubinemia, and recurrent hypoglycemia. The phenotypic spectrum of KCNJ11 mutations is variable and is
likely inﬂuenced by additional genetic and environmental factors.
Copyright © 2009 N. D. Shaw and J. A. Majzoub. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Neonatal diabetes mellitus (NDM) is a rare monogenic
disorder that presents as hyperglycemia, failure to thrive, or
diabetic ketoacidosis in the ﬁrst 6 months of life [1]. The
permanent form of NDM is most commonly caused by a
mutationinKCNJ11,thegeneencodingtheKir6.2subunitof
the ATP-sensitive potassium channel. Kir6.2 assembles with
SURtoformpotassiumchannelsinthebetacell,brain,heart,
and muscle [1].
More than thirty mutations in KCNJ11 have been iden-
tiﬁed [2]. Those mutations producing the most profound
reduction in ATP sensitivity are associated with the most
severe phenotype known as DEND syndrome (developmen-
tal delay, epilepsy, and NDM). A single patient with DEND
harboring a Q52R mutation (c.155A>G) of KCNJ11 was
reported in 2004 [3] (referred to as ISPAD 27), and his
clinical course has been described by Sumnik et al. [4]. This
patient was initially diagnosed with type 1 diabetes in the
ﬁrst week of life and treated with insulin. When his mutation
was discovered at age 4, he was given a trial of glibenclamide
but showed no response. He is currently 9 years old and has
severe developmental delay and epilepsy.
Herein we describe a second case of a patient with a
Q52R mutation in KCNJ11. In addition to NDM, his clinical
course was notable for prematurity, severe hyperbilirubine-
mia and intermittent hypoglycemia unrelated to his diabetes
treatment, features that have not been described in any other
children with NDM. Notably, he did not have any obvious
neurological deﬁcits.
2.CaseReport
Baby Boy SM was the 930g product of a 26.5-wk dichorionic
twin gestation to a 28 year-old G3P0 mother conceived by
in vitro fertilization. At birth, he suﬀered from respiratory
distress and hypotension. His initial blood glucose was
4.8mmol/L, but when switched from oral to parenteral
nutrition (at a glucose infusion rate of 3.6mg/kg/min) on
dayoflife2,hisbloodglucoserosetogreaterthan11mmol/L
(Figure 1).
Consistent with a diagnosis of diabetes, his insulin
and C-peptide levels were inappropriately low (6.3pmol/L
and 0.07nmol/L, resp.) at a time of hyperglycemia (12.3
mmol/L). He required several insulin boluses during the2 International Journal of Pediatric Endocrinology
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Figure 1: Serum glucose, total and direct (conjugated) bilirubin
levels from birth to 3(1/2) months of age. Treatment of hyper-
glycemia detailed above graph. Insulin infusion doses expressed in
units/kg/hour.
Table 1:Laboratoryevaluation of patient SMtodetermineetiology
of hypo- and hyperglycemia.
Analyte Patient Normal value
Insulin (pmol/L)
at blood glucose 12.3mmol/L 6.3 21–136 (fasting)
at blood glucose 1.7mmol/L <1.4 21–136 (fasting)
C-peptide (nmol/L)
at blood glucose 12.3mmol/L 0.07 0.3–1.2 (fasting)
HbA1C at 3mo (%) 5.7 4–6
Pancreatic auto-antibodies (U/L)
GAD 0.64 <0.1
IA2 0.05 <0.1
Cortisol (nmol/L)
baseline 85.5
after 62.5 mcg cortrosyn 717.3 >552
IGF-1 (nmol/L) <3.3 3.3–32
IGFBP-3 (mg/L) 0.9 1.4–4.4
Free thyroxine (pmol/L) 11.6 10.3–23.2
ﬁrst week of life, and a constant infusion of regular
insulin (at 0.05 units/kg/hour) was started on day of life
7. As detailed in Figure 1, his requirement for insulin was
extremelyvariable.Hefrequentlytransitionedfromhyper-to
hypoglycemia despite careful titration of his insulin infusion
and hourly blood glucose measurements. When he became
hypoglycemic, insulin was discontinued, often for several
days, until his blood glucose again rose above 11mmol/L.
He was not consistently on insulin until 3 months of age.
His normal HbA1C (Table 1) likely reﬂects this variability, but
may also be falsely low due to his requirement for red blood
cell transfusions in the setting of liver failure (described
hereafter).
Because of the presentation of diabetes in the neonatal
period, he was tested for monogenic causes of neonatal
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Figure 2: DNA sequence of KCNJ11 from the patient. Substitution
of G for A at nucleotide 155 (c.155A>G) results in Arginine (R)
instead of Glutamine (Q) at amino acid 52 (Q52R).
diabetes. He tested negative for chromosome 6 uniparental
disomy as well as for mutations in glucokinase and insulin
promoterfactor1.Hewasalsofoundtohaveanormalproin-
sulin level (4.1pmol/L). Further testing, however, revealed
ah e t e r o z y g o u sm u t a t i o ni nt h eKCNJ11 gene (c.155A>G,
Q52R, Figure 2) which was not present in his parents or twin
sister. He also had a normal karyotype. His clinical course
and diagnostic studies strongly supported the diagnosis of
NDM; however, his recurrent hypoglycemia was perplexing.
Although a single low insulin level (<1.4pmol/L) at a time
of hypoglycemia (1.7mmol/L) suggested that factors other
than insulin were involved (Table 1), it is still possible
that he had intermittent bursts of insulin secretion which
were undetected due to insulin’s short half-life. Because
KCNJ11 mutations that cause NDM sometimes respond
to sulfonylurea treatment, at 14 weeks of age, glipizide
was added to his insulin therapy at 0.15mg/kg/day and
increased to 0.75mg/kg/day over a 4-day period. Upon
initiation of glipizide treatment, his insulin dose was halved
(0.03 to 0.015 units/kg every 3 hours as needed for blood
glucoses > 11mmol/L), and he required one to three insulin
injections per day (Figure 1). Due to diarrhea and weight
loss (195g which represents nearly 10% of initial body
weight), the medication was discontinued after 10 days.
He was managed solely with insulin thereafter, and at
discharge he required 0.3units/kg/day of Lispro prior to each
meal.
At2monthsofage(correctedage34.5weeks),thepatient
developed liver dysfunction (Figure 1, Table 2). Of note, at
t h i st i m eh eh a db e e no ﬀ of parental nutrition for over
one month. His ALT and AST both rose to over 200IU/L,
his total bilirubin peaked at 376.2µmol/L (direct bilirubin
169.3µmol/L), and he required several doses of fresh frozen
plasma to treat a coagulopathy (PTT > 150 seconds). The
etiology of his liver failure was never found despite an
exhaustive laboratory evaluation. He had a normal lipase
and alpha-1-antitrypsin level, and his newborn screen wasInternational Journal of Pediatric Endocrinology 3
Table 2:Laboratoryevaluation of patient SMtodetermineetiology
of liver failure.
Analyte Patient Normal value
ALT (IU/L)
∗ 266 0–54
AST (IU/L)
∗ 424 16–74
Alkaline Phosphatase (IU/L)
∗ 866 40–300
Gamma-glutamyl transpeptidase (IU/L)
∗ 122 1–78
Bilirubin, total (µmol/L)
∗ 376.2 2–17
Bilirubin, direct (µmol/L)
∗ 169.3 <14
Lipase (IU/L) 8 3–60
Alpha-1-antitrypsin (µmol/L) 24 16–37
PT (s)
∗ 20.5 12.2–14.8
PTT (s)
∗ >150 23.8–36.6
Albumin (g/L) 31 29–48
Total Protein (g/L) 42 44–75
Hepatitis Panel (B, C) NEG NEG
Newborn Screen for Cystic Fibrosis NEG NEG
∗Peak value measured.
negative for cystic ﬁbrosis. Hepatitis B core and surface
antigen and antibody, hepatitis B e antigen, and hepatitis
C antibody were all undetectable, but he had a strongly
positive anti-GAD titer, which may have represented a cross-
reaction with a hepatitis antigen (Table 1)[ 5]. He had no
evidence of adrenal insuﬃciency and was euthyroid. He was
growing well but his IGF-1 and IGFBP-3 levels were low,
likely secondary to impaired synthesis by his compromised
liver(Table 1).Twoliverultrasoundswerenormal,andaliver
biopsy showed diﬀuse, toxic/metabolic injury thought to be
asecondaryprocess.Withsupportivetreatmentandtime,his
liver function improved.
At approximately 3 months of age (corrected age 37
weeks), the patient underwent a formal neurodevelopmental
assessment. Despite his preceding critical illness, he demon-
strated normal passive range of motion of all extremities, a
strong grasp and suck, and was able to ﬁxate on and scan
facesandbringhishandstohismouth.Theonlydeﬁcitnoted
was a decrease in his spontaneous motor activity. By the
time of discharge, at age 4 months of age (corrected age 2.5
weeks), however, he had achieved the same developmental
milestones as had his healthy twin sister.
A diabetes nurse educator taught the patient’s parents
how to administer insulin and to use a glucometer on several
occasions prior to discharge. He saw his pediatrician the day
of discharge and appeared well but died unexpectedly in the
middleofthenight.Therewasnoobviouscauseofdeathand
no autopsy was performed.
3. Discussion
This report describes the unique phenotype of the second
patient with NDM secondary to a Q52R mutation in
KCNJ11. Unlike other patients with NDM, our patient had
intermittent hypoglycemia (in addition to hyperglycemia),
even when not being treated with insulin. Our patient was
clearly at risk for hypoglycemia due to reduced hepatic
glycogenstores associated withprematurity and liver disease.
If these were the only contributing factors, however, one
would expect his hypoglycemic episodes to have clustered
early in the neonatal period, during periods of severe
liver dysfunction, and with longer episodes of fasting. This
is not the pattern depicted in Figure 1:h i sl i v e rf a i l u r e
was progressive rather than episodic, he was prone to
hypoglycemia before his bilirubin rose and after it returned
to normal, and his hypoglycemia occurred both with fasting
and after a meal.
Our patient was also unique in having idiopathic liver
failure. Liver involvement has not been described in any
patient with NDM, including ISPAD27. The majority of
NDMpatients,however,havenotbeenvulnerablepremature
neonates subject to the same physiologic stressors as our
patient, so the liver disease may have been solely related
to factors associated with prematurity including hypop-
erfusion, infection, hypoxia, or drug eﬀects. However, it
is also possible that a KCNJ11 mutation increases one’s
susceptibility to liver failure but is only manifested in
combination with other factors related to prematurity. As
noted previously, Kir6.2 is widely expressed and has been
detected in human liver cell lines [6], but its potential
function in the liver has not been explored.
In summary, this patient represents the second reported
case of NDM secondary to a Q52R mutation in KCNJ11
and the ﬁrst report of NDM accompanied by hypoglycemia
and liver failure. This patient’s normal neurodevelopment,
at least until 4 months (corrected age 2.5 weeks), was
also unexpected given that the only other patient reported
with NDM and this KCNJ11 mutation has DEND. Because
the pathogenesis of developmental delay and epilepsy in
DEND patients remains unknown, we believe that clinicians
taking care of patients with NDM should carefully evaluate
them for intermittent hypoglycemic insults as well as liver
dysfunction.
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